A perfect legal and regulatory storm has been unleashed on the life sciences industry and is greatly impacting IP Due Diligence.

ACI’s 7th Annual Life Sciences IP Due Diligence Summit is devoted to providing corporate and IP counsel with the tools and critical information you need to develop winning strategies and ensure strong, valuable, and protected IP Assets that can hold up under pressure. Our esteemed speakers will provide insights on what to look for during the due diligence process, how to strategize in a shifting landscape, and how to avoid potential patent pitfalls.

CONFERENCE CO-CHAIRS

Tom Irving

Partner
The Marbury Law Group, PLLC

Speaker

Forrester Liddle

Head of Intellectual Property and Legal for US R&D
Novo Nordisk

Develop a new forward thinking, “bespoke” life sciences IP due diligence strategy with insights from a faculty of 40+ leading speakers.

Learn more

Meet over a dozen inhouse counsel who actively work in the IP due diligence space including lawyers Merck, Johnson & Johnson, Teva Pharmaceuticals, Gilead Sciences, and Zentalis Pharmaceuticals.

Learn more

Hear first-hand from deal-makers and investors on what they look for when making a deal and what diligence results may hinder investment.

Learn more
SPECIAL SESSION ON IP DUE DILIGENCE IN THE AGE OF AI WITH

Charles Kim

Deputy Commissioner for Patents
United States Patent and Trademark Office

GAIN INSIGHTS FROM KEY INDUSTRY STAKEHOLDERS INCLUDING

Tashica Williams Amirgholizadeh, Ph.D.

Senior Associate General Counsel, IP, IP Alliance and Due Diligence (IPADD), Team Lead
Gilead Sciences, Inc.

Anna L. Cocuzzo

Managing Counsel, Patents, Boston
Merck

William Vickery

Director of Due Diligence
Servier

Featured Sessions

IP Policy Deep Dive on how Loper, orange book de-listings, the IRA and potential march-in rights are impacting diligence

Spotlight on Terminal Disclaimers and Double Patenting

Cellect and Xencor problem solving Think Tank

Focus on International Diligence Concerns from the UPC to the BIOSECURE Act

Two Exclusive Roundtables focusing on Dealmaking and Investing

SEE WHO ATTENDED IN THE PAST
  • AMRI
  • Allergan plc
  • AtriCure Inc
  • Azurity Pharmaceuticals Inc
  • BONWRx
  • Beck & Thomas
  • Biogen
  • Blaze Bioscience Inc
  • BlueRock Therapeutics
  • Boehringer Ingelheim International GmbH
  • Boston University (CARB-X)
  • Brammer Bio
  • Brinks Gilson & Lione
  • Centre for Drug Research and Development
  • Cipla Limited
  • Clexio Biosciences
  • Codiak BioSciences
  • Dana-Farber Cancer Institute Venture Fund, Binnery Street Capital
  • DRI Capital Inc
  • Dentsply Sirona Inc
  • Dr. Reddys Laboratories
  • Dyno Therapeutics
  • Eisai Inc
  • Eli Lilly & Co
  • Evolve BioSystems
  • Ferring Pharmaceuticals
  • Foghorn Therapeutics
  • Forma Therapeutics Inc
  • Futuragene
  • Genfit
  • Genentech Inc
  • Gilead Sciences
  • Gurnet Point Capital
  • Heliae
  • Hexos Renewals
  • Hikma Pharmaceuticals USA Inc
  • Hoyng Rokh Monegier
  • Immunogen Inc
  • Incyte Corporation
  • Indivior Inc
  • Intellia Therapeutics Inc
  • Ipsen Bioscience Inc
  • Ironwood Pharmaceuticals Inc
  • Jazz Pharmaceuticals
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • KSQ Therapeutics Inc
  • MEDRx
  • Merchant & Gould
  • Merck & Co
  • Mersana Therapeutics
  • MicroVention Inc.
  • Novartis
  • Obalon Therapeutics
  • Pieris Pharmaceuticals Inc
  • Purdue Pharma LP
  • Regeneron Pharmaceuticals Inc
  • ReNAgade Therapeutics
  • Roivant Sciences Inc
  • Rutgers Law School
  • SalioGen Therapeutics
  • Sanofi
  • Sarepta Therapeutics
  • Science Exchange
  • Servier Pharmaceuticals LLC
  • Shire Pharmaceuticals
  • SmartPharm Therapeutics
  • Sumitomo Pharma America Inc
  • Taro Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Third Rock Ventures
  • Transformative
  • Treeline Biosciences
  • US Court of Appeals for Federal Circuit
  • VBI Vaccines Inc
  • Viatris
  • VLP Law Group LLP
  • Wave Life Sciences
  • Zentalis Pharmaceuticals
Testimonials
Quote Icon

Unique high level sessions, good mix of in-house and outside counsel.

Quote Icon

Hearing from professionals involved in due diligence on a daily basis was very informative.

Quote Icon

Great panels, lots of diversity of practice, and lots of seasoned practitioners.

Quote Icon

The design of the event brought us all together along with room intimacy.